Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 3 3Phase NA 2Phase 2/3 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1

Interventions

Docetaxel 7acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 5Prednisone 5Androgen Antagonists 5gallium 68 PSMA-11 4enzalutamide 3bicalutamide 3Triptorelin Pamoate 3Radiosurgery 3Leuprolide 3Goserelin 32-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 3abiraterone 2Zoledronic Acid 2Radiotherapy, Intensity-Modulated 2Radiotherapy 2Mitoxantrone 2Flutamide 2Celecoxib 2Abiraterone Acetate 2satraplatin 1relugolix 1pertuzumab 1nilutamide 1maltodextrin 1luprolide acetate gel depot 1histrelin 1genistein combined polysaccharide 1fluciclovine F-18 1darolutamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Prostatic Neoplasms × Soybean Proteins × Clear all
NCT00765479 2013-09-20

Soy Protein in Preventing Recurrent Cancer in Patients Who Have Undergone Surgery for Stage II Prostate Cancer

National Cancer Institute (NCI)

Phase 2/3 Completed
284 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡